Myasthenic crisis in COVID-19 by Delly, Fadi et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Neurology Articles Neurology 
7-15-2020 
Myasthenic crisis in COVID-19 
Fadi Delly 
Henry Ford Health System, fdelly1@hfhs.org 
Maryam J. Syed 
Robert P. Lisak 
Deepti Zutshi 
Follow this and additional works at: https://scholarlycommons.henryford.com/neurology_articles 
Recommended Citation 
Delly F, Syed MJ, Lisak RP, and Zutshi D. Myasthenic crisis in COVID-19. J Neurol Sci 2020; 414. 
This Article is brought to you for free and open access by the Neurology at Henry Ford Health System Scholarly 
Commons. It has been accepted for inclusion in Neurology Articles by an authorized administrator of Henry Ford 
Health System Scholarly Commons. 
Contents lists available at ScienceDirect
Journal of the Neurological Sciences
journal homepage: www.elsevier.com/locate/jns
Letter to the Editor
Myasthenic crisis in COVID-19
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Dear Editor,
The neurotropic potential and the neurological complications of
coronavirus disease of 2019 (COVID-19) are still being uncovered.
Those documented so far include headaches, acute cerebrovascular
incidents, anosmia, post-infectious disseminated and brainstem en-
cephalitis, viral meningitis [1] and Guillain-Barré Syndrome [2].
Myasthenia gravis (MG) patients are particularly susceptible to infec-
tions causing crises due to the combination of reduced neuromuscular
safety factors adversely affected by pyrexia and the effect of acute in-
flammatory mediators compounded by immunosuppression in many
patients [3,4]. Acute respiratory distress (ARDS) seen in COVID-19
coupled with respiratory muscle failure seen in MG crises may result in
a dire prognosis. We present a case of a 56-year-old woman who de-
veloped MG crisis and concomitant COVID-19.
The patient is a 56-year-old woman with a history of acetylcholine
receptor antibody (AChR-Ab) positive MG for over five years main-
tained on pyridostigmine 60 mg four times daily, prednisone 20 mg
twice a day and intravenous immunoglobulin (IVIG) infusions (650 mg/
kg for two days every two weeks). The patient had refused thymectomy.
She also took hydroxychloroquine 200 mg twice daily for mixed con-
nective tissue disease. Her exacerbations typically consisted of weak-
ness of her lower extremities, ptosis and dysphagia but no history of
mechanical ventilator support. She presented to the emergency de-
partment with dyspnea, fevers, rhinorrhea and diffuse myalgias. She
had 70% oxygen saturation, was placed on 15 L of oxygen on non-
rebreather but continued to deteriorate requiring mechanical ventila-
tion. Initial chest x-ray showed bi-basilar infiltrates compatible with
pneumonia (Fig. 1A). She was started on vancomycin, cefepime, azi-
thromycin and prednisone was increased to 40 mg twice daily. Influ-
enza A and B testing was negative but COVID-19 (confirmed by CDC
COVID-19 real-time RT PCR on Roche cyclers) was reported positive on
day 2 of admission. Antibiotics were stopped and hydroxychloroquine,
200 mg daily was resumed. On Day 3, neurology recommended re-
starting pyridostigmine and IVIG 400 mg/kg for five days. Neurological
examination prior to IVIG was significant for motor strength of 4/5 in
the proximal upper and lower extremities, intact cranial nerves with
speech and swallowing function difficult to assess due to intubation.
Worsening respiratory status and bilateral pulmonary infiltrates re-
quired prone positioning for 16 h on days 6 and 7 (Fig. 1B). Patient
showed improvement on ventilator settings after her fifth IVIG dose on
day 8 and continued to improve over the course of treatment. Patient
was extubated and placed on CPAP on day 13 and 4 L Oxygen by nasal
cannula (NC) on day 15 with chest x-ray showing improved bilateral
infiltrates (Fig. 1C). However, due to worsening proximal weakness of
upper and lower extremities (2/5), she received another course of IVIG
650 mg/kg two days in a row. Repeat COVID-19 testing was positive on
Day 19. By day 25, patient was able to stand, walk 4–5 steps and re-
quired 3 L oxygen by NC with chest x-ray remaining stable (Fig. 1D).
Patient was awaiting placement for subacute rehab facility.
Chest radiographs of bilateral pneumonia progression on days 1(A)
and 6(B) and improvement on days 15(C) and 25(D).
We present this first known case in the literature of MG crises with
simultaneous COVID-19. Recent guidelines for the management of MG
during the COVID-19 pandemic suggest individualized therapy, how-
ever, MG crises has not been addressed as a potential complication of
COVID-19 [4]. While coronavirus infections have not been documented
as a cause of MG crisis, viral infections in general have been reported to
trigger autoimmunity through augmentation of T cell signaling causing
a pro-inflammatory environment due to a hyper-reactive antiviral im-
mune response, epitope spreading and due to the effects of fever on
neuromuscular junction function [5]. A shared component between the
immunopathogenesis of COVID-19 and MG crises is cytokine dysregu-
lation which promotes the increase of pro-inflammatory cytokines and
chemokines that attack organ systems, particularly the lungs which can
result in ARDS [5,6].
IVIG uses pooled normal IgG that works through numerous me-
chanisms, which include: blocking both cytokine production and pa-
thologically activated differentiation of Th1, Th17 and Tfh subsets,
overwhelming the neonatal Fc receptor which in turn causes reduction
in endogenous and exogenous IgG leading to reduction of AChR anti-
bodies, neutralization of autoantibodies by anti-idiotypic antibodies
and inhibition of complement activation [7]. The potential anti-viral
and immune-modulating actions of hydroxychloroquine and IVIG
against COVID-19 are currently under investigation with mixed find-
ings [8]. Hydroxychloroquine is also reported to worsen MG [3]. In our
patient, the combined use of hydroxychloroquine and azithromycin, a
macrolide that aggravates MG, may have caused the worsening of MG,
requiring additional doses of IVIG [5]. Additionally, a potential com-
plication of IVIG is thrombosis and widespread thrombosis has also
been reported in critically ill COVID-19 patients [9,10]. Therefore,
careful administration of IVIG is required in MG patients with
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concomitant COVID-19.
COVID-19 in patients with MG, particularly those who are already
immunosuppressed, raises several therapeutic dilemmas, including side
effects of MG treatments like IVIG and plasma exchange, as well as side
effects of many medications in patients with MG. Ongoing registries of
patients with COVID-19 and MG should prove helpful.
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Fig. 1. Sequential chest radiographs of patient with COVID-19 and myasthenic crises.
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